Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Striverdi Respimat
(United States) [Available]Synonyms :
olodaterol
Class :
Drugs for asthma and COPD & Bronchodilators (Beta2-agonists/ Adrenergic agonists)
Dosage forms & Strengths:
Adult:
Metered dose inhalation solution
2.5 mcg
Safety and efficacy not determined
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may increase the toxic effect of beta2 agonists
may decrease the bronchodilatory effect of beta blockers
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
Beta2-Agonists: they mayincrease the hypokalemic effect when combined with thiazides
Beta2-Agonists: they mayincrease the hypokalemic effect when combined with thiazides
Beta2-Agonists: they mayincrease the hypokalemic effect when combined with thiazides
Beta2-Agonists: they mayincrease the hypokalemic effect when combined with thiazides
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
may increase the hypokalemic effect of thiazide diuretics
may increase the hypokalemic effect of thiazide diuretics
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
spironolactone and hydrochlorothiazide
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may decrease the bronchodilatory effect of beta blockers
may have an increased tachycardic effect when combined with beta2-agonists
atosiban: they may increase the toxic effect of Beta2-Agonists
theophylline derivatives: they may increase the toxic effect of Beta2-Agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
The pharmacological action of olodaterol, a long-acting beta2-adrenergic agonist (LABA), is achieved by binding and activating beta2-adrenergic receptors, which are mostly found in the lungs.
Membrane-bound beta2-adrenergic receptors are typically triggered by endogenous adrenaline through a downstream interaction with an L-type calcium channel.
Protein kinase A (PKA) and cyclic adenosine monophosphate (cAMP) are formed when the receptor is activated, triggering an associated G protein that in turn activates adenylate cyclase.
Frequency defined:
>10%:
Nasopharyngitis (11%)
1%-10%
Skin rash (2%)
Urinary tract infection (3%)
Back pain (4%)
Arthralgia (2%)
Bronchitis (5%)
<1%:
Angina pectoris
Cardiac arrhythmia
Cough
Dermatitis
Fatigue
Variable blood pressure
Restlessness
Nervousness
An increase in mortality from asthma was observed in a placebo-controlled trial using salmeterol.
Acute bronchospasm should not be treated with this medication as a rescue measure.
It is not licensed for the treatment of asthma and its safety and effectiveness in asthmatic patients have not been verified.
Contraindication:
Hypersensitivity
Caution:
Hypokalemia and hyperglycemia
Serious asthma related events
Deterioration of disease and acute episodes
Pregnancy consideration: Some adverse effects were reported in animal studies with olodaterol. It may affect uterine contractility if administer during labor.
Lactation: Excretion of olodaterol in breast milk is not known.
Pregnancy category:
The b1- and b3-adrenergic receptors, which are frequently found in cardiac smooth muscle and adipose tissue, have significantly lower levels of activity than the human beta2-adrenergic receptor, which olodaterol is a strong agonist of in vitro.
Bronchodilation and smooth muscle relaxation in the lungs are brought on by binding to the receptor. It has been demonstrated to effectively reverse active bronchoconstriction.
Even if patient feels good, take olodaterol at the same time every day.
Only use the inhaler that came with your medication; otherwise, you risk not receiving the recommended dosage. Every time you have your prescription filled, use the new inhaler.
Olodaterol is not a rescue for episodes of bronchospasm. Only use inhalation medications that respond quickly to prevent an attack. If you believe your drugs are not doing their job as intended or if your breathing issues worsen quickly, patient should visit a doctor.
Patient information leaflet
Generic Name: olodaterol
Why do we use olodaterol?
Olodaterol recommended as a maintenance bronchodilator for individuals with COPD who are having airflow restriction difficulties.
Olodaterol inhalation is used to manage emphysema and chronic bronchitis, two symptoms of chronic obstructive pulmonary disease (COPD).
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
